Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis

T Olsson, LF Barcellos, L Alfredsson - Nature Reviews Neurology, 2017 - nature.com
Genetic predisposition to multiple sclerosis (MS) only explains a fraction of the disease risk;
lifestyle and environmental factors are key contributors to the risk of MS. Importantly, these …

Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice

JC Souberbielle, JJ Body, JM Lappe, M Plebani… - Autoimmunity …, 2010 - Elsevier
BACKGROUND: There is increasing evidence that, in addition to the well-known effects on
musculoskeletal health, vitamin D status may be related to a number of non-skeletal …

Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis

C Bridel, WN Van Wieringen, H Zetterberg… - JAMA …, 2019 - jamanetwork.com
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

[HTML][HTML] Randomized trial of oral teriflunomide for relapsing multiple sclerosis

P O'Connor, JS Wolinsky, C Confavreux… - … England Journal of …, 2011 - Mass Medical Soc
Background Teriflunomide is a new oral disease-modifying therapy for relapsing forms of
multiple sclerosis. Methods We concluded a randomized trial involving 1088 patients with …

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

B Kornek, MK Storch, R Weissert, E Wallstroem… - The American journal of …, 2000 - Elsevier
Recent magnetic resonance (MR) studies of multiple sclerosis lesions indicate that axonal
injury is a major correlate of permanent clinical deficit. In the present study we systematically …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

C Confavreux, P O'Connor, G Comi… - The Lancet …, 2014 - thelancet.com
Background Teriflunomide is an oral disease-modifying therapy approved for treatment of
relapsing or relapsing–remitting multiple sclerosis. We aimed to provide further evidence for …

Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology

MK Storch, A Stefferl, U Brehm, R Weissert… - Brain …, 1998 - Wiley Online Library
Multiple sclerosis is a chronic inflammatory disease characterized by perivenous
inflammation and focal destruction of myelin. Many attempts have been undertaken …

Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis

F Lundmark, K Duvefelt, E Iacobaeus, I Kockum… - Nature …, 2007 - nature.com
Multiple sclerosis is a chronic, often disabling, disease of the central nervous system
affecting more than 1 in 1,000 people in most western countries. The inflammatory lesions …

Neurofascin as a novel target for autoantibody-mediated axonal injury

EK Mathey, T Derfuss, MK Storch, KR Williams… - The Journal of …, 2007 - rupress.org
Axonal injury is considered the major cause of disability in patients with multiple sclerosis
(MS), but the underlying effector mechanisms are poorly understood. Starting with a …